Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Very low dose Thymoglobulin vs Basiliximab in low-risk kidney transplant induction
TCTR20260601018Phase 4Not yet recruiting
- Sponsor
- Siriraj Hospital
- Start
- May 2026
- Modality
- Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of antithymocyte globulin, basiliximab in end-stage kidney disease (ESKD), sponsored by Siriraj Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
antithymocyte globulinbasiliximab
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on TCTR20260601018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260601018.